Early Decompressive Hemicraniectomy for High-Risk Large Ischemic Core Stroke Post-EVTAcute Ischemic Stroke (AIS), particularly Anterior Circulation Large Vessel Occlusion (LVO), is a major cause of global disability and death. While endovascular thrombectomy (EVT) is the standard first-line treatment for LVO, outcomes remain poor in patients with large ischemic cores (ASPECTS ≤5). Despite high recanalization rates (\>90%), only 14-30% achieve functional independence (mRS 0-2) at 90 days, with 33-50% dead or severely disabled (mRS 5-6). Outcomes worsen dramatically with larger core volumes (e.g., only 4.4% functional independence with cores ≥150mL in SELECT2).A critical complication is Malignant Cerebral Edema (MCE), affecting \~50% of large-core patients post-EVT. MCE triggers a vicious cycle of rising intracranial pressure, reduced perfusion, and brain herniation. It drastically worsens prognosis: functional independence rates plummet (13.3% vs 51.2% without MCE), mortality significantly increases (OR=7.96, p=0.001), and functional outcomes deteriorate (OR=7.83, p=0.008). Strong predictors include low ASPECTS (\<7) and large infarct volume.Decompressive Hemicraniectomy (DHC) is a life-saving intervention for MCE. Landmark trials (DESTINY, DECIMAL, HAMLET) and their meta-analysis show DHC within 24 hours in patients aged 18-60 significantly increases 12-month survival (78% vs 29%, ARR 50%) and rates of ambulatory independence (mRS ≤3: 43% vs 21%, ARR 23%). DESTINY II confirmed benefit in patients \>60, improving functional outcomes (mRS 0-4: 38% vs 16%). Guidelines endorse DHC for large infarcts with deterioration.However, significant challenges persist: DHC is Underutilized: Despite evidence, clinical adoption remains low.Rescue DHC Fails to Improve Outcomes in Post-EVT MCE: Studies report poor functional outcomes (only 20% mRS 0-2) and high mortality (48.6%) with standard medical therapy (SMT) plus rescue DHC after MCE develops. Retrospective data confirms worse outcomes in these patients (mRS 0-2: 16.4% vs 50%; mortality: 46.5% vs 20%) compared to those without MCE. Crucially, rescue DHC itself fails to improve prognosis once MCE is established (mRS 5-6: 64% vs 57.7%; mortality: 48% vs 46.2%).High-Risk Identification: Patients defined as high-risk for MCE (ASPECTS 3-5 + NIHSS≥30 or ASPECTS≤2) have significantly worse 90-day outcomes (mRS 0-2: 23.2% vs 44.6%; mortality: 44% vs 22.7%).Timing is Critical: Rescue DHC is often performed too late, after irreversible neurological damage occurs. Early/Prophylactic DHC, performed before significant edema and herniation develop, offers a potential pathophysiological advantage. It may:Improve cerebral perfusion pressure earlier. Reduce mass effect and edema progression. Mitigate secondary injury (e.g., reduce oxygen-free radicals, excitatory amino acids).Potentially break the ischemic-edema-herniation cycle sooner.Rationale for the Study: While DHC is effective for established MCE in non-EVT contexts and rescue DHC post-EVT is ineffective, high-quality evidence for early prophylactic DHC in high-risk large-core patients after successful EVT is lacking. Current guidelines do not address this specific, high-risk population where MCE incidence is \~50% and outcomes are dismal despite recanalization. Study Aim: This trial will evaluate the efficacy and safety of early prophylactic decompressive hemicraniectomy compared to standard medical treatment (which includes rescue DHC if MCE develops) in AIS-LVO patients at high risk of MCE (defined by ASPECTS and NIHSS criteria) following successful EVT. The goal is to determine if proactive intervention can improve functional outcomes and reduce mortality in this critically ill population where current strategies fail.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
380
Early prophylactic decompressive hemicraniectomy (decompressive hemicraniectomy is required to initiate within 6 hours after completion of mechanical thrombectomy and within 4 hours after randomization).
Xuanwu Hospital, Capital Medical University.
Beijing, China
NOT_YET_RECRUITINGLiaocheng Brain Hospital
Shandong, China
RECRUITINGRate of mRS score of 0-4
Rate of mRS score of 0-4
Time frame: 90 days (±7 days) after randomization
Rate of mRS score of 0-3 Ordinal shift analysis of mRS •Rate of mRS score of 0-2 •Rate of midline shift ≥ 5 mm •Rate of brain herniation Improvement of the NIHSS Rate of neurological deterioration Rate of rescue decompressive hemicraniectomy
mRS score ranges 0-6
Time frame: 90 days (±7 days) after randomization
Ordinal shift analysis of mRS
mRS score ranges 0-6
Time frame: 90 days (±7 days) after randomization
Rate of mRS score of 0-2
mRS score ranges 0-6
Time frame: 90 days (±7 days) after randomization
Rate of midline shift ≥ 5 mm
Based on imaging assessment (e.g., CT, MRI)
Time frame: Within 72 hours after randomization
Rate of brain herniation
e.g., 1 or 2 dilated, fixed pupils; unconsciousness related to edema \[i.e., ≥2 on item 1a on the NIHSS\]; and/or loss of other brain stem reflexes, attributable to edema or herniation according to the Investigator's judgment
Time frame: Within 72 hours after randomization
Improvement of the NIHSS
The NIHSS score range from 0 (no deficit) to 42 (maximum deficit)
Time frame: 5-7 days after randomization or discharge
Rate of neurological deterioration
Defined as increase of NIHSS score ≥4 from baseline
Time frame: 5-7 days after randomization or discharge
Rate of rescue decompressive hemicraniectomy
Control group
Time frame: 5-7 days after randomization or discharge
Length of ICU stay
Residual stay days of ICU
Time frame: Perioperative
Length of hospitalization
Residual stay days of hospitalization
Time frame: Perioperative
Barthel Index
The Barthel Index range from 0 (severe disability) to 100 (no disability)
Time frame: 90 days (±7 days) after randomization
Modified Rankin scale and Barthel Index
The mRS score range from 0 (no disability) to 6 (death), the Barthel Index range from 0 (severe disability) to 100 (no disability)
Time frame: 12 months (±30 days) after randomization
Rate of any intracranial hemorrhage (ICH)
The occurrence of ICH includes the following scenarios: 1. new occurrence of ICH; 2. progression of ICH based on Heidelberg Bleeding Classification.
Time frame: Within 72 hours after randomization
Rate of parenchymal hematoma type 2 intracranial hemorrhage
Time frame: Within 72 hours after randomization
Mortality
Defined as mRS 6
Time frame: 90 days (±7 days) after randomization
Serious Adverse Events
Detailled description noted in study protocol
Time frame: 90 days (±7 days) after randomization
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.